PER® Congress on Hematologic Malignancies (Winter Hem) | Conference

Investigators Push to Leverage Liquid Biopsy As New Standard in Early Detection, Prognosis of Hematologic Malignancies

March 3rd 2022

Leveraging the advances made with liquid biopsies in pantumor assays and specific hematologic cancers has laid the groundwork for the shift in care by using single, or multifaceted approaches for identifying, predicting, and monitoring disease progression.

Targeted Therapies Plus Chemotherapy Provide Path Around Acquired Resistance in AML

February 28th 2022

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

Checkpoint Inhibitors and Bispecifics Build Momentum Throughout Lymphoma

February 28th 2022

Although checkpoint inhibitors and bispecific antibodies have come to represent clinical oncology’s fourth leg of treatment—immunotherapy—there remains much to explore within lymphoma.

Treatment and Sequencing Options Continue to Evolve in Relapsed/Refractory DLBCL

February 28th 2022

The emergence of novel agents, including CAR T-cell therapies and antibody-drug conjugates, plus existing options such as chemoimmunotherapy and bone-marrow transplant, have combined to raise questions about the sequencing of these treatments in patients with diffuse large B-cell lymphoma.

Novel Combination Therapies Show Promise in Managing Early Relapse in Multiple Myeloma

March 2nd 2021

There is building evidence that novel combination therapies could be effective in treating early relapsed multiple myeloma.

Genotyping Offers Insights Into Key Characteristics of ALL Subtypes

March 2nd 2021

Genomic sequencing is a critical step in informing the prognosis of patients with acute lymphoblastic leukemia and more information regarding specific subgroups of ALL, such as lineage ambiguous ALL, could pave the way for more personalized therapies for patients.

Armand Reviews Novel Therapeutics in Relapsed/Refractory Follicular Lymphoma

March 2nd 2021

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

Investigative Interventions Gain Ground in GVHD

March 2nd 2021

With an increased understanding of disease biology, several approaches are under examination to optimize the management of patients with graft-versus-host disease.

New Methods for MRD Testing Help to Predict Relapse Across Multiple Leukemia Subtypes

March 2nd 2021

Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.

BR Retains its Role in Frontline Waldenström Macroglobulinemia Despite the Utility of BTK Inhibitors

March 1st 2021

The treatment landscape of Waldenström macroglobulinemia is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab remains the frontline standard of care for this patient population.

Immunotherapy Is on the Cusp of Major Breakthroughs in Multiple Myeloma

March 1st 2021

Immune therapy has evolved rapidly in multiple myeloma, and the field is on the verge of major improvements in outcomes.

A More Simplified Health Care System is Needed to Provide Value

March 1st 2021

Although scientific advances in hematology and oncology have been extraordinary, the US health care system faces significant challenges in ensuring that patients receive high-quality, cost-effective care.

DiNardo Describes Practical Considerations for the Management of Unfit Patients With AML

February 28th 2021

Several options have emerged for patients with acute myeloid leukemia who are not candidates to receive chemotherapy, with venetoclax-based regimens chief among them.

Targeted Therapies Dominate the Relapsed/Refractory CLL Paradigm

February 27th 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

Early Successes and Remaining Challenges of Harnessing Natural Killer Cells for Cancer Therapy

February 27th 2021

Natural killer cells can offer several advantages over T cells for CAR therapy in that the former uses both a CAR dependent and independent mechanism for tumor eradication, has better safety, and off-the-shelf feasibility—all at a potentially lower cost.

Dr. Martin on Potential Drug-Drug Interactions With BTK Inhibitors in MCL

February 26th 2021

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Raising the Standard Beyond Frontline R-CHOP in DLBCL

February 26th 2021

Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

February 26th 2021

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies

February 26th 2021

Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.

Growing Body of Evidence Underscores the Activity and Safety of CAR T-cell Therapy in ALL

February 25th 2021

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.